Company*
(Country; Symbol)

Funding
Institution

Amount (M)

Type#

Details (Date)


Aastrom
Biosciences
Inc.
(ASTM)

National Cancer Institute

$0.11

Phase I SBIR grant

To study the AastromReplicell System in enhancing the immunostimulatory potency of dendritic cell-based cancer vaccines (9/30)

Acambis plc
(UK; ACAM)

National Institute of Allergy and Infectious Diseases

$131

Contract award

$76M is for development and manufacturing of a modified vaccinia ankara smallpox vaccine, totaling 500,000 doses; a $55M option covers up to 2.5M more single-dose vials (9/30)

Accelrys Inc.
(ACCL)

Northrop Grumman Corp.

ND

Subcontract award

Accerlerys will use statistical modeling technology to help research and develop bioagent detectors for the U.S. Department of Homeland Security (9/1)

Adenosine
Therapeutics
LLC*

Department of Health and Human Services

$0.64

SBIR grant

The two-year grant will support work with the University of Virginia on ATL-146e for treating inflammatory bowel disease (7/20)

Advanced
Vision Therapies
Inc.*

National Institutes of Health

$0.687

Phase I SBIR grants

Three grants to support advancement of gene transfer technology for treating prevalent eye diseases (8/5)

Agencourt
Bioscience
Corp.*

National Institutes of Health

ND

Contract renewal

Two-year renewal under which Agencourt will provide sequencing services for the Mammalian Gene Collection project and the Cancer Genome Anatomy Project at the NIH (8/31)

AlphaVax
Inc.*

National Institute of Allergy and Infectious Diseases

$4.8

Development grant

The three-year grant is for early development of a SARS vaccine (9/13)

Altor
Bioscience
Corp.*

National Cancer Institute

$1

Phase II SBIR grant

Two-year grant will support advancement of soluble T-cell antigen receptor fusions toward clinical development as cancer therapeutics (9/20)

Anadys
Pharmaceuticals
Inc.
(ANDS)

National Institutes of Health

$1.2

Phase II SBIR grant

The two-year grant will support development of antibacterials that inhibit ribosomal function in drug-resistant bacteria (9/21)

Antex Biologics
Inc.
(subsidiary of
Emergent BioSolutions)

National Institute of Allergy and Infectious Diseases

$2

Grant

The grant will be distributed over three years to support development of a dry formulation of the company's Helicobacter pylori vaccine candidate (7/9)

Arexis
AB*
(Sweden)

European Union

ND

Sixth Framework program funding

To support the program on bile salt-stimulated lipase, an enzyme present in human milk, for neonatal applications (9/22)

Avant Immuno-
therapeutics Inc.
(AVAN)

Department of Defense

$2.8

Funding support

Appropriations bill contained funding support for continued development of an oral combination vaccine to protect against anthrax and plague (7/26)

Bavarian
Nordic A/S
(Denmark;
CSE:BAVA)

National Institute of Allergy and Infectious Diseases

$141

Contract

$100M of the contract is for the company to produce 500,000 doses of Imvamune smallpox vaccine within 11 months; the government has an option to buy another 2.5M doses of the MVA vaccine for $41M (9/30)

Biotie Therapies
Oyj*
(Finland)

Tekes (National Technology Agency of Finland)

€1.4 (US$1.7)

Funding support

The money is designed to cover 50% of the cost of a Biotie research program on integrin through February 2006 (7/5)

Blue
Heron
Biotechnology
Inc.*

National Institute of General Medical Science and the National Human Genome Research Institute

$0.138

Phase I SBIR grant

For development of a "universal" restriction enzyme system; for assembling large DNA molecules by ligation of sticky-ended fragments (9/9)

Bolder
BioTechnology
Corp.*
(Canada)

National Cancer Institute

$0.92

Phase I and II SBIR grants

A Phase II grant of $819,961 is for studying long-acting endostatin for treating cancer; a $100,000 Phase I grant is for long-acting VEGF-binding proteins for treating cancer (9/1)

Bolder
BioTechnology
Corp.*
(Canada)

National Institute of Neurological Disorders and Stroke

$0.75

Phase II SBIR grant

To support optimization and manufacturing of a long-acting beta interferon candidate for multiple sclerosis (8/18)

Caprion
Pharmaceuticals
Inc.*
(Canada)

National Institute of Allergy and Infectious Diseases

$13.1

Contract award

Five-year contract in biodefense research to study molecular events that enable bacteria to subvert the immune system (8/10)

Cellerant
Therapeutics
Inc.*

National Institute of Allergy and Infectious Diseases

$0.8

SBIR grant

For work on using adult hematopoietic stem and progenitor cells to treat those exposed to lethal doses of radiation (9/29)

Ceregene
Inc.*

The ALS Association

ND

Funding support

The ALSA will support preclinical studies at Ceregene on viral delivery of insulin-like growth factor 1 for amyotrophic lateral sclerosis (9/15)

Cerus
Corp.
(CERS)

National Institute of Allergy and Infectious Diseases

$3.8

Grant

Three-year grant to develop an anthrax vaccine with greater potency than existing vaccines; $1.4M will be awarded the first year (7/28)

Chemical
Diversity Labs
Inc.*
and Yale
University

National Institutes of Health

ND

Phase I STTR grant

Joint grant is to support discovery of small-molecule inhibitors of the melanocortin-2 receptor, for adrenal gland disorders (8/19)

Chiron Corp.
(CHIR)

National Institute of Allergy and Infectious Diseases

ND

Contract award

Chiron will produce up to 40,000 doses of an H9N2 influenza vaccine; the NIAID will conduct clinical studies to explore safety and immunogenicity (8/17)

Coley
Pharmaceutical
Group Inc.*

National Institute of Allergy and Infectious Diseases

$16.9

Contract award

Five-year contract will fund development of immune-activating drug targeting Toll-like receptors for defense against bioterror agents (9/21)

CombiMatrix
Group
(CBMX)

Department of Defense

$2.3

Contract award

The funding increase brings to $5.9M the amount awarded for development of a sensor system for detecting threatening agents (7/22)

Commonwealth
Biotechnologies
Inc.
(CBTE)

Undisclosed

$1.2

Contract award

Provided fourth year of funding to develop reagents that can be used for detecting select agent pathogens (8/12)

Commonwealth
Biotechnologies
Inc.
(CBTE)

Undisclosed

$0.8M

Contract award

To conduct molecular assays on DNA extracted from samples taken from a two-year human clinical trial (8/12)

Commonwealth
Biotechnologies
Inc.
(CBTE)

Vistronix Inc.

$0.15M

Contract award

Add-on to contract under which CBI uses assays to test for bioagents in mail-sorting facilities (7/1)

Commonwealth
Biotechnologies
Inc.
(CBTE)

BEI Resources

$0.23M

Contract award

Details on the biodefense-related contract were not disclosed (7/1)

Commonwealth
Biotechnologies
Inc.
(CBTE)

Undisclosed U.S. government agency

$0.8M

Contract award

Two-year program involves developing new laboratory analyses for select agent pathogens; details were not disclosed (7/1)

Cryptome
Pharmaceuticals
Ltd.
(Australia;
ASX: CRP)

AusIndustry (Australia)

A$1.95 (US$1.34)

R&D START grant

The grant will fund up to 50 percent of preclinical development of CR001, a naturally occurring peptide, as an alternative to current thrombosis drugs (8/30)

Curis Inc.
(CRIS)

Spinal Muscular Atrophy Foundation

$5.4

Grant

Three-year grant will support work at Curis to develop motor neuron assays and use them to screen for potential drug candidates for treating SMA (9/7)

Cyntellect Inc.*

Not disclosed

$1.5

Phase II SBIR grant

For continued development of RNA interference applications on its LEAP platform (9/14)

Cytogen Corp. (CYTO)

Department of Defense

$0.1

Grant

Thomas Jefferson University was awarded a grant to study Cytogen's Quadramet with hormonal therapy in prostate cancer patients at high risk of the disease spreading to the bone (8/9)

Diffusion
Pharmaceuticals
LLC*

Department of Defense

$1

DoD appropriation

To support the preclinical development of transodium crocetinate for treating illnesses characterized by hypoxia (9/8)

Diffusion
Pharmaceuticals
LLC*

Office of Naval Research

$1.2

Grant

To support the preclinical development of transodium crocetinate for treating hemorrhagic shock (7/28)

Discovery
Partners
International
Inc.
(DPII)

National Institutes of Health

$24

Contract award

To set up and maintain a small-molecule repository to manage and provide up to 1 million compounds to NIH screening centers as part of the NIH Roadmap; the contract is worth $24M if it runs its full term through 2008 (8/23)

Diversa Corp.
(DVSA)

National Institute of Allergy and Infectious Diseases

$1

Grant

Diversa was awarded $1M for the first year of work to discover and develop antibodies to diagnose and treat severe acute respiratory syndrome (9/8)

DNA 2.0 Inc.*

National Human Genome Research Institute

ND

SBIR grant

The grant will support work to increase the fidelity and reduce the cost of synthetic DNA manufacture (9/21)

DOR BioPharma
Inc.
(AMEX:
DOR)

National Institute of Allergy and Infectious Diseases

$5.2

Grant

For further development of DOR's ricin vaccine, RiVax (9/13)

Emergent
Technologies
Inc.*

Oklahoma Center for Advancement of Science and Technology

$0.27

Grant

Pure Protein LLC, an Emergent portfolio company, will use the money to develop new assays to validate epitopes it discovered (8/3)

Epimmune Inc.
(EPMN)

National Institute of Allergy and Infectious Diseases

$2.8

Contract award

The NIAID exercised a three-year contract option for Epimmune to conduct preclinical development of a multi-epitope malaria vaccine (7/13)

EpiVax Inc.*

National Institute of Allergy and Infectious Diseases

$0.86

BioDefense Phase I SBIR grant

For development of a genome- derived, epitope-driven tularemia (Francisella tularensis) vaccine (9/13)

Gambro AB
(Sweden; SSE:
GAMB)

U.S. Department of Defense

$2

Grant

Gambro subsidiary Navigant Biotechnologies Inc. will use the money to develop a transport- able pathogen- eduction and blood safety system, applicable to use by the military (8/25)

Genaera
Inc.
(GENR)

National Eye Institute

$0.1

Phase I SBIR grant

To further develop squalamine-related aminosterols as anti-angiogenics for treating wet age- related macular degeneration (9/30)

Genaera Inc.
(GENR)

National Institute of Diabetes and Digestive and Kidney Diseases

$0.1

Phase I SBIR grant

To support initial development of a small-molecule aminosterol (trodusquemine) for treating obesity (9/29)

Genomatica
Inc.*

Department of Energy

$0.75

Phase II SBIR grant

To enhance the SimPheny software platform for use in supporting metabolic research (9/28)

GenPhar Inc.*

U.S. Army

$4.9

Contract expansion

Funding increased from $1.1M to $6M over two years for work on multivalent vaccines for Marburg and Ebola viruses (7/30)

Genetronics
Biomedical
Corp.
(AMEX:
GEB)

National Institutes of Health

$0.1

Phase I SBIR grant

To support research in the use of electroporation technology in vascular gene therapy (8/31)

Hematech
LLC*

U.S. Army's Joint Vaccine Acquisition Program

$3

Funding support

Appropriations bill included funding to support a large-scale bovine production system for fully human polyclonal antibodies (7/28)

ID Biomedical Corp. (Canada; TSE:IDB)

National Institutes of Health

$9.5

Grant

To support further development and early trials of its cell culture-based influenza vaccine (9/29)

ID Biomedical Corp. (Canada; TSE:IDB)

National Institutes of Health

$8

Grant

Up to $8M will be awarded for development of a nasally administered plague vaccine based on the company's Proteosome delivery technology (9/21)

ID Biomedical
Corp.
(Canada;
TSE:IDB)

Canadian government

C$30 (US$23.3)

Contract award

ID Biomedical was selected to supply meningitis C vaccine to the Canadian government over two years; theC$30M value includes a third-year option (9/13)

Illumina Inc.
(ILMN)

National Institute of Allergy and Infectious Diseases

$1.2

Phase II SBIR grant

For continued development of high-multiplex arrays to profile protein activity in small volumes of cells or biological fluids (8/11)

Infectech Inc.
(subsidiary of
Nutra Pharma
Corp.; OTC BB:
NPHC)

Ohio Agricultural Research and Development Center

ND

Research grant

Ohio State University researchers will use the grant to test a diagnostic for Mycobacterium avium; the technology OSU will use is owned by Infectech (8/30)

Introgen
Therapeutics
Inc.
(INGN)

National Cancer Institute

$0.7

Grant

The three-year grant will support evaluation of the anti-angiogenis properties of mda-7/IL-24; colborators at M.D. Anderson Cancer Center will lead the research (9/21)

Macropore
Biosurgery Inc.
(FSE:XMP)

National Institutes of Health

$0.75

SBIR grant

For second phase of a project to study the role of adipose-derived regenerative cells in treating heart attack (7/27)

Molecular
Insight
Pharmaceuticals
Inc.*
and the
University of
Maryland

National Institutes of Health

ND

Grant

To develop molecular imaging agents to detect and monitor the activity of angiotensin-convering enzyme in patients with congestive heart failure (8/26)

MycoLogics
Inc.*

Naitonal Institutes of Health

ND

Phase I SBIR grant

To identify a lead drug compound for human trials for the treatment of leishmaniasis (8/20)

Myriad Genetics Inc. (MYGN)

National Institute of Allergy and Infectious Diseases

$14.2

Contract award

Myriad will characterize pathogen-host protein interactions to discover targets for new vaccines, drugs and diagnostics; the interaction and validation data will be made available to the R&D community, while Myriad retains the rights to any resulting diagnostic and therapeutic targets (7/8)

Nanospectra Biosciences Inc.*

National Institute of Standards and Technology

$2

Advanced Technology Program award

To develop an integrated approach to the diagnosis and treatment of cancer using a new class of near-infrared absorbing nano-particles called nanoshells (9/29)

Neuro3d*
(France)

The French Agency for Innovation (ANVAR)

€0.9 (US$1.1)

Research support

To support further development of the Phase I phosphodiesterase- 4 inhibitor ND1251 for treating depression (7/15)

NsGene A/S*
(Denmark)

Michael J. Fox Foundation for Parkinson's Research

$3

Grant

To support proof-of-concept studies of encapsulated cell therapy in Parkinson's disease; the funding will be given as mile-stones are achieved (7/1)

Northfield
Laboratories
Inc.
(NFLD)

Department of Defense

$1.4

Defense appropriations funding

For continued development of PolyHeme, a human hemoglobin-based blood substitute; for potential use on battlefields (8/26)

Nura Inc.*

National Institutes of Health

$1

Fast-track grant

The grant will be used to apply technology in G protein- coupled receptors to study anxiety (9/22)

OriGene
Technologies
Inc.*

National Human Genome Research Institute

ND

Phase I SBIR grant

The award will support work with the company's TrueClone collection of full-length cDNA clones (9/23)

Pain
Therapeutics
Inc.
(PTIE)

National Institutes of Health

$0.1

Innovation research grant

The grant will support company research and development in neuropathic pain (7/12)

Paratek
Pharmaceuticals
Inc.*

National Institute of Allergy and Infectious Diseases

$2

Phase II SBIR grant

Two-year grant to support development of tetracycline-based compounds for malaria (7/7)

Perlegen
Sciences
Inc.
(AFFX)

National Human Genome Research Institute

$6

Grant

Perlegen will genotype more than 2.25M single nucleotide polymorphisms in 270 samples from four populations being studied by the HapMap Project (9/30)

Perlegen
Sciences
Inc.
(AFFX)

National Institution Aging

ND

Grant

For a whole-genome association study of Alzheimer's disease (9/13)

Perlegen
Sciences Inc.
(AFFX)

National Institute of Mental Health

ND

Grant

For the first phase of a high-density genome-wide study to determine the genetics of autism; it will use DNA samples collected by the Autism Genetic Resource Exchange (8/19)

Pharmos
Corp
(PARS).

Office of the Chief Scientist (Israel)

$0.482

Grant

To support development of drug candidates from its program on peripheral cannabinoid-2 recep- tor agonists (9/7)

ProteomTech
Inc.*

National Cancer Institute

$0.75

Phase II SBIR grant

To support development of an anti-angiogenesis protein drug, vascular endothelial growth inhibitor (8/24)

ProteoTech
Inc.*

National Institute of Arthritis and Musculoskeletal and Skin Disorders

$0.265

Phase I SBIR grant

To fund further development of small molecules believed to inhibit a variety of amyloid diseases (9/24)

ProteoTech
Inc.*

National Institute on Aging

$0.52

Phase I SBIR grant

To analyze the regulation of proteoglycan genes and proteins and their role in the pathogenesis of amyloid plaque development in Alzheimer's disease (8/4)

PTC
Therapeutics
Inc.*

Parent Project Muscular Dystrophy

$1

Grant

PTC will apply its GEMS technology to identify small-molecule compounds to treat Duchenne muscular dystrophy; PTC and PPMD already selected target genes with potential relevance (9/2)

QRxPharma
Pty. Ltd.*
(Australia)

Australian Research Council

$3.2

Linkage Discovery grant

QRxPharma and the University of Queensland will use the money for their work to identify active compounds by studying the venom of Australian snakes (7/7)

Receptor
Logic Ltd.*

National Institute of Standards and Technology

$2

Advanced Technology Program award

Three-year award will fund development of a profiling and immunotherapy platform targeting breast cancer (9/30)

Revivicor Inc.*

National Institute of Standards and Technology

$1.8

Advanced Technology Program award

To use gene knockout and somatic nuclear transfer technologies to inactivate antibody-producing genes in pigs, and replacing them with human equivalents (9/29)

RheoGene Inc.*

National Institute of Standards and Technology

$2

Advanced Technology Program award

To develop techniques for site-specific insertion and control of therapeutic genes in human adult neural stem cells to treat incurable ocular diseases (9/29)

Samaritan
Pharmaceuticals
Inc.
(OTC BB:SPHC)

National Institute of Neurological Disorders and Stroke

$0.188

STTR grant

The grant supports work at Samaritan and Georgetown University on a diagnostic based on the correlation between DHEA pre-cursor levels and Alzheimer's disease (7/12)

Sangart Inc.*

National Heart, Lung and Blood Institute and the Department of Defense

$1.3

Grant

The grant will support research of the oxygen carrier Hemospan for hypovolemic circulatory collapse (9/8)

Scynexis Inc.*

National Institute on Drug Abuse

$3

Contract award

Award for up to $3M to produce bulk drug substances for NIDA's program to develop medications for illicit drug dependency (7/22)

SIGA
Technologies
Inc.
(SIGA)

U.S. Air Force

$4

Contract award

SIGA was named prime contractor on a $4M project to create systems for the rational development of products against biological terrorism threats (9/14)

SIGA
Technologies
Inc.
(SIGA)

National Institutes of Health

$12

Grants

SIGA got two two-year grants to support development of biowarfare defense assets in the area of antivirals that were acquired from ViroPharma Inc. (8/25)

Sinovac Biotech
Ltd.
(China;
OTC BB:SNVBF)

Chinese government

$1.2

Research support

The award increases to $2.3M government funding support for the company's SARS vaccine development program (7/20)

SomaGenics
Inc.*

National Institute of General Medical Sciences

$0.315

Grant

For in vitro selection of the RNA Lassos capable of specific binding to mRNA targets (8/1)

StemCells Inc.
(STEM)

National Institutes of Health

$0.465

STTR grant

StemCells collaborators at the McLaughlin Research Institute got the grant to study human central nervous system stem cells in mouse models of Alzheimer's disease (9/20)

StemCells Inc.
(STEM)

National Institutes of Health

$1.4

Grant

StemCells collaborators at the University of California at Irvine got the grant to study human central nervous system stem cell grafts in treating spinal cord injuries (9/20)

Transkaryotic
Therapies
Inc.
(TKTX)

FDA's Office of Orphan Products Development

$0.3

Development grant

To support an ongoing pivotal trial of the enzyme-replacement therapy iduronate-2-sulfatase for Hunter's syndrome (9/28)

Velcura
Therapeutics
Inc.*

National Institute of Diabetes and Digestive and Kidney Diseases

$1.45

Grant

To support research on the mechanisms by which primitive cells develop into mature bone-forming cells (7/30)

Verta Ltd.*
(Russia)

U.S. Civilian Research and Development Foundation

$0.3

Grant

To evaluate the therapeutic potential of SCV-07 in a hepatitis C virus proof-of-concept trial in Russia (8/25)

Znomics Inc.*

National Human Genome Research Institute and the National Institute of Diabetes and Digestive and Kidney Diseases

$1.53

Phase II SBIR grant

The grant will fund completion of the company's zebrafish insertional mutation library for use in drug and target discovery (9/22)


Notes:

* Indicates a privately held company.

Currency conversions reflect values at the time of a deal's announcement.

# SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer.

Unless otherwise indicated, symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange.

No Comments